To identify alternative mechanisms of PARPi resistance, we generated orthotopic allografts using tumor cells derived from genetically engineered mouse models (GEMMs) of Brca1- or Bard1-deficient breast cancer (Shakya et al, 2008). This evidence concerns the gene BRCA1 and neoplasm.